Compare Eni SpA (E) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Zimmer Biomet Holdings Inc — how do they compare? Eni SpA trades at $48.37 (market cap $70.34B), while Zimmer Biomet Holdings Inc trades at $92.35 (market cap $17.44B). The key difference: Eni SpA is far larger — about 4× Zimmer Biomet Holdings Inc's market cap, and Eni SpA pays the higher dividend (4.99%). Which is the better fit depends on your goals.
| E | ZBH | |
|---|---|---|
Market Cap | $70.34B | $17.44B |
Sector | Energy | Health |
52-Week High | $57.61 | $107.71 |
52-Week Low | $32.93 | $79.58 |
Enterprise Value | $89.25B | $24.49B |
Dividend Yield | 4.99% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $49.55, up 0.22% with a bullish technical signal supported by moving averages. The company shows stable cash flow generation with $238M net cash flow in 2025 and maintains a dividend of $0.63. Recent strategic expansions into renewable fuels, lithium, and energy trading through partnerships with BMW, Mercuria, and UKAEA highlight diversification efforts. Valuation metrics appear reasonable with P/E of 21.6 and EV/EBITDA of 3.83, though revenue has declined from $132.5B in 2022 to $82.15B in 2025.
The outlook balances strategic growth initiatives against revenue pressures. Opportunities exist in energy transition projects and trading expansion, but risks include oil price volatility and execution challenges. Analyst sentiment is mixed with 34.6% buy ratings versus 61.5% hold, suggesting cautious optimism. The stock's investment case hinges on successful diversification while managing core energy market exposure.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
